One-stop Oncolytic Virus Therapy Development Services from Creative Biolabs Cover All R&D Aspects

New York, US, September 25, 2019 Creative Biolabs, a dynamic biotech company focusing on oncolytic virus field for years, now offers one-stop Oncolytic Virus Therapy Development Services, including oncolytic virus construction, oncolytic virus engineering, oncolytic virus validation.

Oncolytic viruses (OVs) that can selectively replicate in and kill cancer cells while leaving the normal tissue uninfected are proved a highly efficient way to induce immune responses against tumor cells. Supported by the fact that a broad diversity of DNA and RNA viruses in oncolytic viruses, scientists at Creative Biolabs can engineer them to be armed with immuno-modulatory transgenes or combined with other immunotherapies, providing a diversified and flexible platform for researchers and industrial clients.

Creative Biolabs provides a broad range of oncolytic virus construction scope including but not limited to Adenovirus, Herpes Simplex Virus, Measles Virus, Vaccinia Virus, Vesicular Stomatitis Virus, and Adeno-Associated Virus. Adenovirus can be modified through transcriptional targeting or post-transcriptional modification. Herpes Simplex Virus (HSV) can be engineered by inserting immune regulatory element Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) into the virus genome (T-Vec). Vaccinia virus can also be engineered as oncolytic virus by mutation of Thymidine Kinase (TK) and Vaccinia Growth Factor (VGF) to attenuate the pathogenicity and increase tumor-specific replication. JX-594 is one of vaccinia virus strains expressing GM-CSF and showed promising clinical efficacy in Phase I and Phase II trials.

Scientists at Creative Biolabs who have been engaged in one-stop solution of oncolytic virus engineering are proficient at manipulating the oncolytic viruses to alter the capsid to reduce pathogenicity and immunogenicity, secret antibody to boost the anti-tumor immune response, express cytokine/chemokine to attract immune cells migration to the tumor site, and even to be loaded with immune checkpoint inhibitors.

Apart from the above-mentioned innovative strategy to satisfy the unique needs of clients, a series of premade oncolytic viruses are available at Creative Biolabs, including but not limited to adenovirus (AdV), vesicular stomatitis virus (VSV), herpes simplex virus (HSV), vaccinia virus (VACV) for oncolytic virotherapy research, equipped with rapid, accurate design and construction, featured by diversified functional validations. Based on years of cooperation with numerous researchers and clients, Creative Biolabs has completed a comprehensive system to guarantee maximum adenovirus production with timely delivery

More information can be reached at https://www.creative-biolabs.com/oncolytic-virus/

About Creative Biolabs

Taking advantage of the OncoVirapy™ platform, Creative Biolabs provides customized, standardized, and reliable and high-quality oncolytic virus therapy development services for clients globally. The service covers all aspects from virus engineering, cell biology to animal testing with a special emphasis on virus engineering and in vitro and in vivo validation. To study the oncolytic efficacy and safety of oncolytic virus, scientists in Creative Biolabs has developed a comprehensive set of in vitro and in vivo assays.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/oncolytic-virus/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: One-stop Oncolytic Virus Therapy Development Services from Creative Biolabs Cover All R&D Aspects